Rating Change
Barclays reiterated its Overweight rating on Celldex Therapeutics, Inc. (NASDAQ:CLDX) on August 07, 2026.
reiterateNASDAQ:CLDX
Barclays Reiterates Overweight Rating on Celldex Therapeutics, Inc. (CLDX)
Barclays reiterated its Overweight rating on Celldex Therapeutics, Inc. (NASDAQ:CLDX) on August 07, 2026.
At publication ·
What changed
Celldex Therapeutics, Inc. (NASDAQ:CLDX) · reiterate
- Firm
- Barclays
- Rating
- Overweight to Overweight
- Price at event
- $41.71
- Market capitalization
- $1.9B
At a glance
Key takeaways
- Barclays reiterated an Overweight rating on Celldex Therapeutics (CLDX) on August 7, 2026, with the stock trading at $41.71 and a market capitalization of $1.9 billion.
Market Context
Celldex Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $41.71 with a market capitalization of $1.9B.
Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Celldex Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Celldex Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 07, 2026 | Morgan Stanley | Overweight | N/A |
| Aug 07, 2026 | Barclays | Overweight | N/A |
| Jul 29, 2026 | Wells Fargo | Overweight | N/A |
| Jul 22, 2026 | Morgan Stanley | Overweight | N/A |
| Jul 22, 2026 | Wells Fargo | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View CLDX Stock Page
Frequently Asked Questions
What does the Overweight rating mean for CLDX?
A rating of Overweight from Barclays reflects the analyst's outlook on Celldex Therapeutics, Inc. (NASDAQ:CLDX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the CLDX forecast page.